Search results
Results from the WOW.Com Content Network
The bottom line represents benzodiazepine deaths that did not involve opioids. [1] Benzodiazepines have a wide therapeutic index and taken alone in overdose rarely cause severe complications or fatalities. [13] [25] More often than not, a patient who inadvertently takes more than the prescribed dose will simply feel drowsy and fall asleep for a ...
Low-dose, slow subcutaneous flumazenil administration is a safe procedure for patients withdrawing from long-term, high-dose benzodiazepine dependency. [24] It has a low risk of seizures even amongst those who have experienced convulsions when previously attempting benzodiazepine withdrawal.
Flumazenil is an imidazobenzodiazepine that can help mediate and antagonize the effects of benzodiazepines. It can be used in anaesthesia as well as intensive care. [6] Flumazenil raises concerns with its tendency to induce benzodiazepine withdrawal, and symptoms include seizures and agitation.
[citation needed] Bemegride and flumazenil are used to treat drug overdoses (of barbiturates and benzodiazepines respectively), but may cause convulsions if the dose is too high. [8] [9] Convulsants are also widely used in scientific research, for instance in the testing of new anticonvulsant drugs. Convulsions are induced in captive animals ...
Digoxin poisoning, Oleander ingestion [8] Diphenhydramine hydrochloride and benztropine mesylate: Extrapyramidal reactions associated with antipsychotics: 100% Ethanol or fomepizole: Ethylene glycol poisoning and methanol poisoning: Flumazenil: Benzodiazepine overdose: 100% oxygen or hyperbaric oxygen therapy (HBOT) Carbon monoxide poisoning ...
Protracted benzodiazepine withdrawal has been observed to occur in some individuals prescribed benzodiazepines. [8] [9] Drug use, including alcohol and prescription drugs, can induce symptomatology which resembles mental illness. This can occur both in the intoxicated state and during the withdrawal state.
Flumazenil is a benzodiazepine antagonist and blocks the binding of benzodiazepines to gamma-aminobutyric acid receptors. Similarly to naloxone, flumazenil has a short half-life, and this needs to be taken into account because the patient may exhibit central nervous depression after the antidote has been cleared.
A study into the effects of the benzodiazepine receptor antagonist, flumazenil, on benzodiazepine withdrawal symptoms persisting after withdrawal was carried out by Lader and Morton. Study subjects had been benzodiazepine-free for between one month and five years, but all reported persisting withdrawal effects to varying degrees.